{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:17:46Z","timestamp":1791400666712,"version":"4.3.3"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["psy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.psychres.2015.09.019","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T01:13:33Z","timestamp":1442279613000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders"],"prefix":"10.1016","volume":"230","author":[{"given":"Sarah G.","family":"Helton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk W.","family":"Lohoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/14622416.9.6.655","article-title":"Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence","volume":"9","author":"Anton","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"17","key":"10.1016\/j.psychres.2015.09.019_bib2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.019_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/B978-0-444-62619-6.00030-6","article-title":"Pharmacologic treatment of alcoholism","volume":"125","author":"Anton","year":"2014","journal-title":"Handb. Clin. Neurol."},{"issue":"11","key":"10.1016\/j.psychres.2015.09.019_bib5","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/j.1530-0277.2012.01807.x","article-title":"Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes","volume":"36","author":"Anton","year":"2012","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib6","first-page":"8","article-title":"Topiramate in the treatment of alcohol dependence: a meta-analysis","volume":"38","author":"Arbaizar","year":"2010","journal-title":"Actas Esp. Psiquiatr."},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.janxdis.2007.03.001","article-title":"Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder","volume":"22","author":"Book","year":"2008","journal-title":"J. Anxiety Disord."},{"issue":"7","key":"10.1016\/j.psychres.2015.09.019_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","article-title":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review","volume":"99","author":"Bouza","year":"2004","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cpr.2005.11.005","article-title":"Relapse to alcohol and drug use among individuals diagnosed with co-occurring mental health and substance use disorders: a review","volume":"26","author":"Bradizza","year":"2006","journal-title":"Clin. Psychol. Rev."},{"issue":"3","key":"10.1016\/j.psychres.2015.09.019_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.ALC.0000156129.98265.57","article-title":"Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder","volume":"29","author":"Brady","year":"2005","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"7","key":"10.1016\/j.psychres.2015.09.019_bib12","doi-asserted-by":"crossref","first-page":"e01","DOI":"10.4088\/JCP.0706e01","article-title":"Prevalence and consequences of dual diagnosis","volume":"67","author":"Buckley","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.euroneuro.2013.10.004","article-title":"Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond","volume":"24","author":"Caputo","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2015.09.019_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis","volume":"17","author":"Chamorro","year":"2012","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib15","first-page":"101","article-title":"Variation in mu-opioid receptor gene as a moderator of naltrexone treatment to reduce heavy drinking in a high functioning cohort","volume":"1","author":"Chen","year":"2013","journal-title":"J. Alcohol Drug Depend."},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol"},{"issue":"3","key":"10.1016\/j.psychres.2015.09.019_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1360-0443.2004.00964.x","article-title":"Recovery from DSM-IV alcohol dependence: United States","volume":"100","author":"Dawson","year":"2005","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0973-1229.58820","article-title":"The pharmacotherapy of alcohol dependence: a state of the art review","volume":"8","author":"De Sousa","year":"2010","journal-title":"Mens Sana Monogr."},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsat.2007.05.012","article-title":"An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence","volume":"34","author":"De Sousa","year":"2008","journal-title":"J. Subst. Abuse Treat."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1530-0277.2010.01156.x","article-title":"Genome-wide association study of alcohol dependence implicates a region on chromosome 11","volume":"34","author":"Edenberg","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"11","key":"10.1016\/j.psychres.2015.09.019_bib21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism. A Veterans Administration cooperative study","volume":"256","author":"Fuller","year":"1986","journal-title":"J. Am. Med. Assoc."},{"issue":"13","key":"10.1016\/j.psychres.2015.09.019_bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.psychres.2015.09.019_bib23","first-page":"592","article-title":"Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study","volume":"22","author":"Gastpar","year":"2002"},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1530-0277.2007.00339.x","article-title":"Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study","volume":"31","author":"Gelernter","year":"2007","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"7","key":"10.1016\/j.psychres.2015.09.019_bib25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrg1635","article-title":"The genetics of addictions: uncovering the genes","volume":"6","author":"Goldman","year":"2005","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.psychres.2015.09.019_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0376-8716(95)01160-4","article-title":"Comorbidity between DSM-IV alcohol-use disorders and major depression \u2013 results of a national survey","volume":"39","author":"Grant","year":"1995","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"10.1016\/j.psychres.2015.09.019_bib27","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/archpsyc.61.11.1107","article-title":"Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions","volume":"61","author":"Grant","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2015.09.019_bib28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/archpsyc.64.7.830","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions","volume":"64","author":"Hasin","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib29","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1017\/S0033291797005643","article-title":"Genetic and environmental contributions to alcohol dependence risk in a national twin sample: consistency of findings in women and men","volume":"27","author":"Heath","year":"1997","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/pgs.15.15","article-title":"Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders","volume":"16","author":"Helton","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.psychres.2015.09.019_bib31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/archpsyc.64.7.783","article-title":"Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression","volume":"64","author":"Hu","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/09595230600944461","article-title":"Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs","volume":"25","author":"Jane-Llopis","year":"2006","journal-title":"Drug Alcohol Rev."},{"issue":"8","key":"10.1016\/j.psychres.2015.09.019_bib33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/14656566.7.8.1065","article-title":"A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence","volume":"7","author":"Johnson","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib34","first-page":"741","article-title":"Naltrexone long-acting formulation in the treatment of alcohol dependence","volume":"3","author":"Johnson","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"issue":"9","key":"10.1016\/j.psychres.2015.09.019_bib35","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.ALC.0000139823.30096.52","article-title":"A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"9370","key":"10.1016\/j.psychres.2015.09.019_bib36","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.psychres.2015.09.019_bib37","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"J. Am. Med. Assoc."},{"issue":"10","key":"10.1016\/j.psychres.2015.09.019_bib38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.biopsych.2013.10.020","article-title":"Genetic variation in the atrial natriuretic peptide transcription factor GATA4 modulates amygdala responsiveness in alcohol dependence","volume":"75","author":"Jorde","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2015.09.019_bib40","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1038\/tp.2014.103","article-title":"Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate","volume":"4","author":"Karpyak","year":"2014","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1369-1600.2012.00482.x","article-title":"Association of GATA4 sequence variation with alcohol dependence","volume":"19","author":"Karpyak","year":"2014","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/tpj.2010.51","article-title":"Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate","volume":"11","author":"Kiefer","year":"2011","journal-title":"Pharmacogenomics J."},{"issue":"12","key":"10.1016\/j.psychres.2015.09.019_bib43","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0006-3223(02)01427-0","article-title":"A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function","volume":"52","author":"Kohnke","year":"2002","journal-title":"Biol. Psychiatry"},{"issue":"19","key":"10.1016\/j.psychres.2015.09.019_bib44","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2174\/138161210791516431","article-title":"Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment","volume":"16","author":"Krampe","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1369-1600.2012.00471.x","article-title":"Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment","volume":"18","author":"Kranzler","year":"2013","journal-title":"Addict. Biol."},{"issue":"10","key":"10.1016\/j.psychres.2015.09.019_bib46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1017\/S1461145714000510","article-title":"GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink","volume":"17","author":"Kranzler","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib47","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/adb.12007","article-title":"5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity","volume":"18","author":"Kranzler","year":"2013","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JCP.0b013e31820465fa","article-title":"A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype","volume":"31","author":"Kranzler","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism","volume":"171","author":"Kranzler","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/10550490701756120","article-title":"Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials","volume":"17","author":"Kranzler","year":"2008","journal-title":"Am. J. Addict."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1530-0277.2009.00913.x","article-title":"Association of markers in the 3\u2032 region of the GluR5 kainate receptor subunit gene to alcohol dependence","volume":"33","author":"Kranzler","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.jcp.0000194620.61868.35","article-title":"Sertraline treatment of co-occurring alcohol dependence and major depression","volume":"26","author":"Kranzler","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib53","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JCP.0b013e3181ac5213","article-title":"Targeted naltrexone for problem drinkers","volume":"29","author":"Kranzler","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.psychres.2015.09.019_bib54","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","article-title":"Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"24","key":"10.1016\/j.psychres.2015.09.019_bib55","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"345","author":"Krystal","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5292","key":"10.1016\/j.psychres.2015.09.019_bib56","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","article-title":"Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region","volume":"274","author":"Lesch","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib58","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1530-0277.2008.00884.x","article-title":"Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study","volume":"33","author":"Mann","year":"2009","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"10","key":"10.1016\/j.psychres.2015.09.019_bib59","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1586\/14737175.7.10.1265","article-title":"Long-acting injectable naltrexone for the treatment of alcohol dependence","volume":"7","author":"Mannelli","year":"2007","journal-title":"Expert Rev. Neurother."},{"issue":"1\u20132","key":"10.1016\/j.psychres.2015.09.019_bib60","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drugalcdep.2011.05.010","article-title":"Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population","volume":"119","author":"Martins","year":"2011","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","article-title":"Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation","volume":"40","author":"Mason","year":"2006","journal-title":"J. Psychiatr. Res."},{"issue":"8","key":"10.1016\/j.psychres.2015.09.019_bib62","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1139\/y01-037","article-title":"Regulation of the ANF and BNP promoters by GATA factors: lessons learned for cardiac transcription","volume":"79","author":"McBride","year":"2001","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib63","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.jcp.0000095346.32154.41","article-title":"Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial","volume":"23","author":"Moak","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2015.09.019_bib64","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1360-0443.2006.01555.x","article-title":"Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial","volume":"101","author":"Morley","year":"2006","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib65","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1517\/14656566.2014.876008","article-title":"Current pharmacological treatment approaches for alcohol dependence","volume":"15","author":"Muller","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib66","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/JCP.0b013e31825ddbe6","article-title":"Functional polymorphism of the dopamine beta-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients","volume":"32","author":"Mutschler","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib67","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/jcp.0b013e31814ce50d","article-title":"Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment","volume":"27","author":"O'Malley","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.psychres.2015.09.019_bib68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2015.09.019_bib69","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","article-title":"A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients","volume":"28","author":"Oslin","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib70","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2015.09.019_bib71","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/ajmg.b.31118","article-title":"Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder","volume":"153B","author":"Perroud","year":"2010","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"issue":"4","key":"10.1016\/j.psychres.2015.09.019_bib72","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/npp.2011.283","article-title":"Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence","volume":"37","author":"Petrakis","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib73","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","article-title":"A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence","volume":"167","author":"Pettinati","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/ajp.156.1.34","article-title":"Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins","volume":"156","author":"Prescott","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2015.09.019_bib75","unstructured":"Prevention, C.f.D.C.a., 2014. Alcohol Use and Health. \u3008http:\/\/www.cdc.gov\/alcohol\/fact-sheets\/alcohol-use.htm\u3009."},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1037\/a0015700","article-title":"A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers","volume":"17","author":"Ray","year":"2009","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2015.09.019_bib77","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1530-0277.2000.tb04573.x","article-title":"Predictors of compliance with naltrexone among alcoholics","volume":"24","author":"Rohsenow","year":"2000","journal-title":"Alcohol.\u2014Clin. Exp. Res."},{"issue":"9","key":"10.1016\/j.psychres.2015.09.019_bib78","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.psychres.2015.09.019_bib79","article-title":"Opioid antagonists for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.psychres.2015.09.019_bib80","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4088\/JCP.08r04062gry","article-title":"Topiramate in the treatment of substance-related disorders: a critical review of the literature","volume":"71","author":"Shinn","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib81","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2015.09.019_bib82","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"12","author":"Srisurapanont","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2015.09.019_bib83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.brainres.2011.08.005","article-title":"The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response","volume":"1415","author":"Su","year":"2011","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.psychres.2015.09.019_bib84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrg3240","article-title":"Genetic architectures of psychiatric disorders: the emerging picture and its implications","volume":"13","author":"Sullivan","year":"2012","journal-title":"Nat. Rev. Genet."},{"issue":"19","key":"10.1016\/j.psychres.2015.09.019_bib85","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199905133401907","article-title":"Drug therapy for alcohol dependence","volume":"340","author":"Swift","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1530-0277.2007.00546.x","article-title":"A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?","volume":"32","author":"Thomas","year":"2008","journal-title":"Alcohol.\u2014Clin. Exper. Res."},{"issue":"1","key":"10.1016\/j.psychres.2015.09.019_bib87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004714-199202000-00004","article-title":"Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone)","volume":"12","author":"Tollefson","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2015.09.019_bib88","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archgenpsychiatry.2009.83","article-title":"Genome-wide association study of alcohol dependence","volume":"66","author":"Treutlein","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2015.09.019_bib89","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch. Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2015.09.019_bib90","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11920-014-0544-y","article-title":"Anxiety and substance use disorders: co-occurrence and clinical issues","volume":"17","author":"Vorspan","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"issue":"6","key":"10.1016\/j.psychres.2015.09.019_bib91","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response","volume":"348","author":"Weinshilboum","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2015.09.019_bib101","unstructured":"World Health Organization (2014). Global Status on Alcoholism and Health. http:\/\/apps.who.int\/iris\/bitstream\/10665\/112736\/1\/9789240692763_eng.pdf?ua=1."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115303255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115303255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T03:05:32Z","timestamp":1691982332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178115303255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0165178115303255"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2015.09.019","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2015.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}